NCT02905994View on ClinicalTrials.gov

Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2016

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions
AML
Interventions
DRUG

Volasertib

Polo-Like Kinase Inhibitor

DRUG

Cytarabine

Standard chemotherapy at dosage and schedule for 7+3 induction

DRUG

Idarubicin

Standard chemotherapy at dosage and schedule for 7+3 induction

PROCEDURE

Bone Marrow Biopsy

Bone marrow biopsy assessments scheduled during induction to assess response

Trial Locations (2)

02114

Massachusetts general Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT02905994 - Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter